Announced Thu, 23 Jul · 13:23 IST
Solara Active Pharma Q1 FY27 profit up 55% YoY at Rs 16.31 Cr
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-8.1%1-day move
₹537.80
prior close
₹540.65
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.8-2.0-1.4-1.1-8.1-6.6————————
Up moveDown movePending
AI summary
Solara Active Pharma Q1 FY27 consolidated revenue Rs 381.60 Cr, up about 19.5% YoY from Rs 319.15 Cr. Net profit up around 55% at Rs 16.31 Cr vs Rs 10.52 Cr. EPS Rs 3.52 vs Rs 2.46. Exceptional gain Rs 0.86 Cr from gratuity impact. Accumulated losses Rs 286.21 Cr; going concern basis retained. Rights issue raised Rs 442.73 Cr of Rs 449.95 Cr target. CRAMS and Polymers demerger into wholly owned Synthix Global progressing. Deloitte issued unmodified review.
Likely market impact
Strong YoY profit and revenue growth. Going concern retained despite accumulated losses. Demerger plan progressing positively for shareholders.